Remove Headlines Markets-Regulations
article thumbnail

WCG Clinical Announces Relaunch of FDAnews as the Premier Source for Drug and Device Insights

WCG Clinical

Readers who are not yet subscribed for premium content can visit the website daily for free headlines or sign up for a collection of the week’s free stories with the newsletters FDAnews Drug Weekly or FDAnews Device Weekly. Individual subscriptions , customized multi-user, and company licenses to FDAnews are also available.

article thumbnail

What Does Google’s Move to Responsive Search Ads for Paid Search Mean for Pharma?

Intouch Solutions

Let’s talk about what that means for pharma marketers! Why Pharma Marketers Should Care About RSAs RSAs are a text ad format that requires an increased number of headline and description line variations than ETAs require. Among the concerns that pharma marketers face: The RSA ad format will be new to most MLR reviewers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Coronavirus pharma news round-up 21/08/20

pharmaphorum

New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week.

article thumbnail

Evaluate’s Orphan Drug Report 2022

pharmaphorum

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Revising legislation. Positive projections.

Drugs 52
article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

In pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. In turn, the acquiring company will help the novel drugs navigate the complexities and costs of regulations and benefit from market access and economies of scale.

article thumbnail

FIFA Cases Hold Lessons for FDA-Regulated Companies – Organizations can be Victims of Their Own Employees’ Criminal Conduct

FDA Law Blog

However, a good faith effort by the company to comply with applicable statutes and regulations as well as federal health care program requirements, demonstrated by an effective compliance program, significantly reduces the risk of unlawful conduct and any penalties that result from such behavior.

article thumbnail

Pfizer files tick-borne encephalitis shot with FDA

pharmaphorum

Pfizer may have been making headlines with the COVID vaccine it developed with BioNTech, but it’s not the only infectious disease the big pharma is targeting. The FDA has granted a Priority Review, where the regulator aims to make a decision within six months instead of the standard 10 month period.